Locally Delivered Metformin & Rosuvastatin for Treatment of Intrabony Defects in Chronic Periodontitis
Status:
Completed
Trial end date:
2017-02-23
Target enrollment:
Participant gender:
Summary
Metformin (MF), a biguanide group of anti-diabetic drug has been shown to enhance osteoblasts
differentiation and inhibit osteoclast differentiation in vitro, thus may exhibit a
favourable effect on alveolar bone. Statins are one of the lipid lowering drugs that help in
reducing cholesterol levels in the body by specifically inhibiting 3-hydroxy-3-methylglutaryl
coenzyme A reductase; which is a rate limiting enzyme for cholesterol synthesis. Rosuvastatin
(RSV) have shown to have bone stimulatory and anti-inflammatory effects.Statins are one of
the lipid lowering drugs that help in reducing cholesterol levels in the body by specifically
inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase; which is a rate limiting enzyme
for cholesterol synthesis. Rosuvastatin (RSV) and atorvastatin (ATV) have shown to have bone
stimulatory and anti-inflammatory effects.. The present study aims to explore the efficacy of
1.2% RSV and 1MF gel as a local drug delivery and redelivery system as an adjunct to scaling
and root planing (SRP) for the treatment of intrabony defects.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Government Dental College and Research Institute, Bangalore